Abstract:Platelets are small anucleated blood cells primarily known for their vital hemostatic role. Allogeneic platelet concentrates (PCs) collected from healthy donors are an essential cellular product transfused by hospitals to control or prevent bleeding in patients affected by thrombocytopenia or platelet dysfunctions. Platelets fulfill additional essential functions in innate and adaptive immunity and inflammation, as well as in wound-healing and tissue-repair mechanisms. Platelets contain mitochondria, lysosomes, dense granules, and alpha-granules, which collectively are a remarkable reservoir of multiple trophic factors, enzymes, and signaling molecules. In addition, platelets are prone to release in the blood circulation a unique set of extracellular vesicles (p-EVs), which carry a rich biomolecular cargo influential in cell–cell communications. The exceptional functional roles played by platelets and p-EVs explain the recent interest in exploring the use of allogeneic PCs as source material to develop new biotherapies that could address needs in cell therapy, regenerative medicine, and targeted drug delivery. Pooled human platelet lysates (HPLs) can be produced from allogeneic PCs that have reached their expiration date and are no longer suitable for transfusion but remain valuable source materials for other applications. These HPLs can substitute for fetal bovine serum as a clinical grade xeno-free supplement of growth media used in the in vitro expansion of human cells for transplantation purposes. The use of expired allogeneic platelet concentrates has opened the way for small-pool or large-pool allogeneic HPLs and HPL-derived p-EVs as biotherapy for ocular surface disorders, wound care and, potentially, neurodegenerative diseases, osteoarthritis, and others. Additionally, allogeneic platelets are now seen as a readily available source of cells and EVs that can be exploited for targeted drug delivery vehicles. This article aims to offer an in-depth update on emerging translational applications of allogeneic platelet biotherapies while also highlighting their advantages and limitations as a clinical modality in regenerative medicine and cell therapies.

Engineering Unactivated Platelets for Targeted Drug Delivery

Engineering Platelet-Mimicking Drug Delivery Vehicles

Engineered Platelets: Advocates for Tumor Immunotherapy

Platelet-derived biomaterials for targeted drug delivery and tissue repair

Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects

Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond

Recent advances in platelet engineering for anti-cancer therapies

Advancement of Platelet-Inspired Nanomedicine

Engineered platelets-based drug delivery platform for targeted thrombolysis

Drug Targeting Via Platelet Membrane-Coated Nanoparticles.

Engineered Platelets for Cancer Therapy

Platelet membrane-based and tumor-associated platelettargeted drug delivery systems for cancer therapy

Remote-Loaded Platelet Vesicles for Disease-Targeted Delivery of Therapeutics

Platelets As Delivery Systems for Disease Treatments

Platelet‐Drug Conjugates Engineered via One‐step Fusion Approach for Metastatic and Postoperative Cancer Treatment

From bench to bedside: Platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery

Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation

Platelet-inspired Medicine for Tumor Therapyplatelet-Inspired Medicine for Tumor Therapy

Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery

Preparation of Targeted Platelet Carrier and Its Antitumor Effect

Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models